Publications by authors named "A Clavert"

Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e.

View Article and Find Full Text PDF

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is part of the treatment strategy for some patients with high-risk lymphoma by improving survival with an acceptable toxicity profile. Although the BEAM (BCNU, etoposide, cytarabine, and melphalan) intensification regimen is the most used, the optimal dosing for each drug is unclear. Here, we retrospectively compared the outcome of 110 patients receiving higher (400 mg/m, n = 69) or lower (200 mg/m, n = 41) etoposide and cytarabine doses in our institution between 2012 and 2019.

View Article and Find Full Text PDF
Article Synopsis
  • Rituximab treatment is more effective than the 'watch and wait' approach for low-tumor burden follicular lymphoma, improving progression-free survival (PFS) but maintenance therapy raised concerns about resource use and patient adherence.
  • A study compared intravenous (IV) rituximab and subcutaneous (SC) rituximab adminstration in patients, demonstrating better 4-year PFS rates in the experimental SC group (58.1% vs 41.2%).
  • While high exposure to rituximab during the first three months led to improved response rates, time to next treatment (TTNT) and overall survival (OS) showed no significant differences between the two approaches.
View Article and Find Full Text PDF
Article Synopsis
  • Extranodal NK/T-cell lymphoma, nasal type is a rare and aggressive cancer with a traditionally poor outlook, but a study explored a new treatment combining MGAD chemotherapy with targeted radiotherapy.
  • In this study of 35 newly diagnosed patients, 91% achieved complete remission, with promising long-term survival rates of 71% at 2 years and 53% at 5 years.
  • While some patients faced manageable side effects and a third relapsed within about 14.5 months, the short treatment approach showed effectiveness and tolerability for this challenging condition.
View Article and Find Full Text PDF